Bluejay Diagnostics Files 8-K Report

Ticker: BJDX · Form: 8-K · Filed: 2025-10-09T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, 8-k

TL;DR

Bluejay Diagnostics filed an 8-K on Oct 3, 2025, reporting a material definitive agreement.

AI Summary

On October 3, 2025, Bluejay Diagnostics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

Why It Matters

This filing indicates a significant event for Bluejay Diagnostics, Inc., potentially involving a new material agreement that could impact its business operations and financial standing.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report of a material definitive agreement and does not inherently present new risks without further details on the agreement itself.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement filed by Bluejay Diagnostics, Inc.?

The filing does not specify the details of the material definitive agreement, only that one has been entered into as of October 3, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on October 3, 2025.

Where are Bluejay Diagnostics, Inc.'s principal executive offices located?

The principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

What is the SEC file number for Bluejay Diagnostics, Inc.?

The SEC file number is 001-41031.

What is the state of incorporation for Bluejay Diagnostics, Inc.?

Bluejay Diagnostics, Inc. is incorporated in Delaware.

Filing Stats: 750 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2025-10-09 06:05:30

Filing Documents

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 3, 2025, Bluejay Diagnostics, Inc. (the "Company") entered into an agreement (the "Amendment") to amend its Master Service Agreement and the Master Supply Agreement with Sanyoseiko Co., Ltd. ("Sanyoseiko"). The Amendment was entered into in connection with Bluejay expanding SanyoSeiko's role in helping to commercialize Bluejay's Symphony platform, a near-patient testing system designed to provide rapid and reliable results for key biomarkers such as IL-6 in sepsis management. Pursuant to statements of work that the Company has begun to Sanyoseiko under these agreements, as amended by the Amendment, Sanyoseiko will provide end-to-end support for the Symphony platform, including supporting the manufacturing redevelopment process for analyzers and cartridges (with hardware, software, and design updates), managing raw material sourcing and vendor compliance, and serving as the Company's contract manufacturing organization for analyzers, cartridges, and related components. In this capacity, Sanyoseiko will oversee fulfillment, kit assembly, labeling, packaging, shipping, and quality control of manufactured products, while also providing regulatory and quality management support, and equipment storage and maintenance. The foregoing descriptions of the Master Service Agreement, the Master Supply Agreement and the Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are filed as Exhibit 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 9, 2025, the Company issued a press release in connection with the matters discussed herein under item 1.01. A copy of that press release is furnished with this report as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Master Supply Agreement dated July 30, 2021, between Bluejay Diagnostics, Inc. and Sanyoseiko Co., Ltd. 10.2 Master Service Agreement dated July 30, 2021, between Bluejay Diagnostics, Inc. and Sanyoseiko Co., Ltd. 10.3 Agreement to Amend Master Supply Agreement and Master Service Agreement, dated October 3, 2025, between Bluejay Diagnostics, Inc. and Sanyoseiko Co., Ltd. 99.1 Press Release, dated October 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Bluejay Diagnostics, Inc. By: /s/ Neil Dey Neil Dey President and Chief Executive Officer Date: October 9, 2025 2

View on Read The Filing